• Je něco špatně v tomto záznamu ?

Development and validation of a prognostic score integrating remote heart failure symptoms and clinical variables in mortality risk prediction after myocardial infarction: the PragueMi score

P. Wohlfahrt, D. Jenča, V. Melenovský, J. Stehlik, J. Mrázková, M. Šramko, M. Kotrč, M. Želízko, V. Adámková, J. Piťha, J. Kautzner

. 2024 ; 31 (14) : 1713-1720. [pub] 20241010

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, validační studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003909

Grantová podpora
NV 19-09-00125 Ministry of Health of the Czech Republic
LX22NPO5104 National Institute for Research of Metabolic and Cardiovascular Diseases
European Union-Next Generation EU

AIMS: While heart failure (HF) symptoms are associated with adverse prognosis after myocardial infarction (MI), they are not routinely used for patients' stratification. The primary objective of this study was to develop and validate a score to predict mortality risk after MI, combining remotely recorded HF symptoms and clinical risk factors, and to compare it against the guideline-recommended Global Registry of Acute Coronary Events (GRACE) score. METHODS AND RESULTS: A cohort study design using prospectively collected data from consecutive patients hospitalized for MI at a large tertiary heart centre between June 2017 and September 2022 was used. Data from 1135 patients (aged 64 ± 12 years, 26.7% women), were split into derivation (70%) and validation cohort (30%). Components of the 23-item Kansas City Cardiomyopathy Questionnaire and clinical variables were used as possible predictors. The best model included the following variables: age, HF history, admission creatinine and heart rate, ejection fraction at hospital discharge, and HF symptoms 1 month after discharge including walking impairment, leg swelling, and change in HF symptoms. Based on these variables, the PragueMi score was developed. In the validation cohort, the PragueMi score showed superior discrimination to the GRACE score for 6 months [the area under the receiver operating curve (AUC) 90.1, 95% confidence interval (CI) 81.8-98.4 vs. 77.4, 95% CI 62.2-92.5, P = 0.04) and 1-year risk prediction (AUC 89.7, 95% CI 83.5-96.0 vs. 76.2, 95% CI 64.7-87.7, P = 0.004). CONCLUSION: The PragueMi score combining HF symptoms and clinical variables performs better than the currently recommended GRACE score.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003909
003      
CZ-PrNML
005      
20250206104759.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/eurjpc/zwae114 $2 doi
035    __
$a (PubMed)38497201
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Wohlfahrt, Peter $u Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague 140 21, Czech Republic $u First Medical School, Charles University, Katerinska 1660/32, Prague 120 00, Czech Republic $1 https://orcid.org/000000032390526X
245    10
$a Development and validation of a prognostic score integrating remote heart failure symptoms and clinical variables in mortality risk prediction after myocardial infarction: the PragueMi score / $c P. Wohlfahrt, D. Jenča, V. Melenovský, J. Stehlik, J. Mrázková, M. Šramko, M. Kotrč, M. Želízko, V. Adámková, J. Piťha, J. Kautzner
520    9_
$a AIMS: While heart failure (HF) symptoms are associated with adverse prognosis after myocardial infarction (MI), they are not routinely used for patients' stratification. The primary objective of this study was to develop and validate a score to predict mortality risk after MI, combining remotely recorded HF symptoms and clinical risk factors, and to compare it against the guideline-recommended Global Registry of Acute Coronary Events (GRACE) score. METHODS AND RESULTS: A cohort study design using prospectively collected data from consecutive patients hospitalized for MI at a large tertiary heart centre between June 2017 and September 2022 was used. Data from 1135 patients (aged 64 ± 12 years, 26.7% women), were split into derivation (70%) and validation cohort (30%). Components of the 23-item Kansas City Cardiomyopathy Questionnaire and clinical variables were used as possible predictors. The best model included the following variables: age, HF history, admission creatinine and heart rate, ejection fraction at hospital discharge, and HF symptoms 1 month after discharge including walking impairment, leg swelling, and change in HF symptoms. Based on these variables, the PragueMi score was developed. In the validation cohort, the PragueMi score showed superior discrimination to the GRACE score for 6 months [the area under the receiver operating curve (AUC) 90.1, 95% confidence interval (CI) 81.8-98.4 vs. 77.4, 95% CI 62.2-92.5, P = 0.04) and 1-year risk prediction (AUC 89.7, 95% CI 83.5-96.0 vs. 76.2, 95% CI 64.7-87.7, P = 0.004). CONCLUSION: The PragueMi score combining HF symptoms and clinical variables performs better than the currently recommended GRACE score.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a srdeční selhání $x mortalita $x diagnóza $x patofyziologie $7 D006333
650    _2
$a hodnocení rizik $7 D018570
650    12
$a infarkt myokardu $x mortalita $x diagnóza $7 D009203
650    _2
$a senioři $7 D000368
650    _2
$a prognóza $7 D011379
650    _2
$a rizikové faktory $7 D012307
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a prospektivní studie $7 D011446
650    _2
$a časové faktory $7 D013997
650    _2
$a metody pro podporu rozhodování $7 D003661
655    _2
$a časopisecké články $7 D016428
655    _2
$a validační studie $7 D023361
700    1_
$a Jenča, Dominik $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic $u Third Medical School, Charles University, Prague, Czech Republic
700    1_
$a Melenovský, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Stehlik, Josef $u Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
700    1_
$a Mrázková, Jolana $u Experimental Medicine Centre, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Šramko, Marek $u First Medical School, Charles University, Katerinska 1660/32, Prague 120 00, Czech Republic $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Kotrč, Martin $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Želízko, Michael $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Adámková, Věra $u Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague 140 21, Czech Republic
700    1_
$a Piťha, Jan $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Kautzner, Josef $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic $u Medical and Dentistry School, Palacký University, Olomouc, Czech Republic $1 https://orcid.org/0000000216326182 $7 xx0037112
773    0_
$w MED00188754 $t European journal of preventive cardiology $x 2047-4881 $g Roč. 31, č. 14 (2024), s. 1713-1720
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38497201 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104755 $b ABA008
999    __
$a ok $b bmc $g 2263576 $s 1239916
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 31 $c 14 $d 1713-1720 $e 20241010 $i 2047-4881 $m European journal of preventive cardiology $n Eur J Prev Cardiol $x MED00188754
GRA    __
$a NV 19-09-00125 $p Ministry of Health of the Czech Republic
GRA    __
$a LX22NPO5104 $p National Institute for Research of Metabolic and Cardiovascular Diseases
GRA    __
$p European Union-Next Generation EU
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace